Maruyama Riichiroh, Yokoyama Hideki, Seto Takashi, Nagashima Seiji, Kashiwabara Kosuke, Araki Jun, Semba Hiroshi, Ichinose Yukito
Kyushu Yamaguchi Thoracic Oncology Group, Kyushu Cancer Center, Minami-ku, Fukuoka, Japan.
J Thorac Oncol. 2007 Jan;2(1):65-8. doi: 10.1097/JTO.0b013e31802c8260.
Malignant pericardial effusion (MPE) causes cardiac tamponade and an extremely poor outcome unless it is well controlled. The effect of pericardial drainage and the intra-pericardial instillation of bleomycin on the control of MPE was examined in this prospective multi-institutional phase II trial.
In eligible patients with cytologically defined MPE resulting from non-small cell lung cancer, the pericardial effusion of such cases was continuously drained. After complete drainage, 10 mg of bleomycin was then locally instilled via a catheter. The catheter was then removed if the total amount of drainage was less than 30 ml/day. If the catheter could not be removed within 5 days after treatment, bleomycin was administered one more time.
Among the 22 patients who entered this trial, the tube drainage catheter was successfully removed from 17 patients with one instillation, whereas four required such instillation twice and one required such instillation three times. No severe adverse events were observed, except for constrictive pericarditis, which resulted in the treatment-related death of one patient. The control rate of pericardial effusion was 95% +/- 0.09 (95% confidence interval). No restoration of pericardial effusion was observed during the follow-up period or until death from any cause. Median survival time from the beginning of the protocol was 17.9 weeks.
Pericardial drainage followed by the instillation of bleomycin was found to be a safe and effective method for the management of MPE associated with non-small cell lung cancer.
恶性心包积液(MPE)会导致心脏压塞,若控制不佳则预后极差。在这项前瞻性多机构II期试验中,研究了心包引流及心包内注射博来霉素对控制MPE的效果。
对于经细胞学确诊由非小细胞肺癌导致的MPE的符合条件的患者,持续引流此类病例的心包积液。完全引流后,经导管局部注入10毫克博来霉素。若每日引流量少于30毫升,则拔除导管。若治疗后5天内无法拔除导管,则再次注射博来霉素。
在进入该试验的22例患者中,17例患者经一次注射后成功拔除引流管,4例需要注射两次,1例需要注射三次。除1例因缩窄性心包炎导致与治疗相关的死亡外,未观察到严重不良事件。心包积液的控制率为95%±0.09(95%置信区间)。在随访期间或直至因任何原因死亡,均未观察到心包积液复发。从方案开始的中位生存时间为17.9周。
心包引流后注射博来霉素被发现是治疗与非小细胞肺癌相关的MPE的一种安全有效的方法。